Cite
HARVARD Citation
Kay, J. et al. (n.d.). OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. Annals of the rheumatic diseases. p. 136. [Online].